First Manhattan’s Viking Therapeutics VKTX Stock Holding History

First Manhattan’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-120	Closed	-$9.84K	–	1304
2024 Q1	$9.84K	Buy	+120	New	+$5.34K	﹤0.01%	1110
2022 Q4	–	Sell	-1,400	Closed	-$3K	–	1791
2022 Q3	$3K	Hold	1,400	–	–	﹤0.01%	1401
2022 Q2	$4K	Buy	1,400 +400	+40%	+$990	﹤0.01%	1380
2022 Q1	$3K	Hold	1,000	–	–	﹤0.01%	1464
2021 Q4	$4K	Hold	1,000	–	–	﹤0.01%	1417
2021 Q3	$6K	Hold	1,000	–	–	﹤0.01%	1369
2021 Q2	$5K	Buy	+1,000	New	+$5.94K	﹤0.01%	1399
2018 Q4	–	Sell	-201,853	Closed	-$3.52M	–	1445
2018 Q3	$3.52M	Sell	201,853 -332,900	-62%	-$3.96M	0.02%	305
2018 Q2	$5.07M	Buy	534,753 +116,000	+28%	+$772K	0.03%	256
2018 Q1	$1.83M	Buy	+418,753	New	+$2.32M	0.01%	371

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

First Manhattan's VKTX Position: Q2 2024 in Review

First Manhattan sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 120 shares — an estimated $9.84K sold.

First Manhattan first reported a position in VKTX in Q1 2018 and held it in 10 quarters. The position peaked at $5.07M in Q2 2018. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

First Manhattan reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 120 Viking Therapeutics shares in Q2 2024, an estimated $9.84K.
First Manhattan first reported a position in Viking Therapeutics in Q1 2018 and held it in 10 quarters.
First Manhattan's Viking Therapeutics position peaked at $5.07M in Q2 2018.
387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.